Suppr超能文献

慢性阻塞性肺疾病的范式:表型、免疫生物学及以血管疾病为重点的治疗

Paradigms in chronic obstructive pulmonary disease: phenotypes, immunobiology, and therapy with a focus on vascular disease.

作者信息

Schivo Michael, Albertson Timothy E, Haczku Angela, Kenyon Nicholas J, Zeki Amir A, Kuhn Brooks T, Louie Samuel, Avdalovic Mark V

机构信息

Department of Internal Medicine, University of California Davis School of Medicine, Sacramento, California, USA.

Center for Comparative Respiratory Biology and Medicine, Genome and Biomedical Sciences Facility, University of California Davis, Davis, California, USA.

出版信息

J Investig Med. 2017 Aug;65(6):953-963. doi: 10.1136/jim-2016-000358. Epub 2017 Mar 3.

Abstract

Chronic obstructive pulmonary disease (COPD) is a complex and heterogeneous syndrome that represents a major global health burden. COPD phenotypes have recently emerged based on large cohort studies addressing the need to better characterize the syndrome. Though comprehensive phenotyping is still at an early stage, factors such as ethnicity and radiographic, serum, and exhaled breath biomarkers have shown promise. COPD is also an immunological disease where innate and adaptive immune responses to the environment and tobacco smoke are altered. The frequent overlap between COPD and other systemic diseases, such as cardiovascular disease, has influenced COPD therapy, and treatments for both conditions may lead to improved patient outcomes. Here, we discuss current paradigms that center on improving the definition of COPD, understanding the immunological overlap between COPD and vascular inflammation, and the treatment of COPD-with a focus on comorbid cardiovascular disease.

摘要

慢性阻塞性肺疾病(COPD)是一种复杂的异质性综合征,是全球主要的健康负担。基于大型队列研究,COPD表型最近出现,以满足更好地描述该综合征的需求。尽管全面的表型分析仍处于早期阶段,但种族、影像学、血清和呼出气体生物标志物等因素已显示出前景。COPD也是一种免疫性疾病,对环境和烟草烟雾的先天性和适应性免疫反应会发生改变。COPD与其他全身性疾病(如心血管疾病)之间的频繁重叠影响了COPD的治疗,针对这两种疾病的治疗可能会改善患者的预后。在此,我们讨论当前的范式,这些范式围绕改善COPD的定义、理解COPD与血管炎症之间的免疫重叠以及COPD的治疗展开,重点关注合并的心血管疾病。

相似文献

1
Paradigms in chronic obstructive pulmonary disease: phenotypes, immunobiology, and therapy with a focus on vascular disease.
J Investig Med. 2017 Aug;65(6):953-963. doi: 10.1136/jim-2016-000358. Epub 2017 Mar 3.
3
Chronic obstructive pulmonary disease and obstructive sleep apnea: overlaps in pathophysiology, systemic inflammation, and cardiovascular disease.
Am J Respir Crit Care Med. 2009 Oct 15;180(8):692-700. doi: 10.1164/rccm.200903-0347PP. Epub 2009 Jul 23.
4
Management of Chronic Obstructive Pulmonary Disease in Patients with Cardiovascular Diseases.
Drugs. 2017 May;77(7):721-732. doi: 10.1007/s40265-017-0731-3.
5
Strategies for reducing the risk of cardiovascular disease in patients with chronic obstructive pulmonary disease.
High Blood Press Cardiovasc Prev. 2015 Jun;22(2):103-11. doi: 10.1007/s40292-015-0078-3. Epub 2015 Feb 6.
8
Disease Burden of Patients with Asthma/COPD Overlap in a US Claims Database: Impact of ICD-9 Coding-based Definitions.
COPD. 2017 Apr;14(2):200-209. doi: 10.1080/15412555.2016.1257598. Epub 2017 Jan 19.
9
Distribution of clinical phenotypes in patients with chronic obstructive pulmonary disease caused by biomass and tobacco smoke.
Arch Bronconeumol. 2014 Aug;50(8):318-24. doi: 10.1016/j.arbres.2013.12.013. Epub 2014 Feb 25.
10
Distribution and characteristics of COPD phenotypes - results from the Polish sub-cohort of the POPE study.
Int J Chron Obstruct Pulmon Dis. 2018 May 17;13:1613-1621. doi: 10.2147/COPD.S154716. eCollection 2018.

引用本文的文献

1
Identification and validation of biomarkers related to mitophagy in chronic obstructive pulmonary disease.
Mol Med Rep. 2025 Apr;31(4). doi: 10.3892/mmr.2025.13458. Epub 2025 Feb 14.
2
Effectiveness of glycopyrronium bromide in the treatment of small airway dysfunction: A retrospective study.
SAGE Open Med. 2022 Dec 23;10:20503121221145605. doi: 10.1177/20503121221145605. eCollection 2022.
3
Identification of Dysregulated Mechanisms and Candidate Gene Markers in Chronic Obstructive Pulmonary Disease.
Int J Chron Obstruct Pulmon Dis. 2022 Mar 4;17:475-487. doi: 10.2147/COPD.S349694. eCollection 2022.
5
Development of a biomarker mortality risk model in acute respiratory distress syndrome.
Crit Care. 2019 Dec 16;23(1):410. doi: 10.1186/s13054-019-2697-x.
6
Features of Oxidative and Nitrosative Metabolism in Lung Diseases.
Oxid Med Cell Longev. 2019 May 22;2019:1689861. doi: 10.1155/2019/1689861. eCollection 2019.
7
The Salford Lung Study: a pioneering comparative effectiveness approach to COPD and asthma in clinical trials.
Pragmat Obs Res. 2017 Sep 20;8:175-181. doi: 10.2147/POR.S144157. eCollection 2017.

本文引用的文献

1
Long-term safety of tiotropium delivered by Respimat SoftMist™ Inhaler: patient selection and special considerations.
Ther Clin Risk Manag. 2016 Sep 21;12:1433-1444. doi: 10.2147/TCRM.S109011. eCollection 2016.
2
Natural History of Myocardial Function in an Adult Human Population: Serial Longitudinal Observations From MESA.
JACC Cardiovasc Imaging. 2016 Oct;9(10):1164-1173. doi: 10.1016/j.jcmg.2016.01.038. Epub 2016 Sep 14.
4
Persistence of circulating endothelial microparticles in COPD despite smoking cessation.
Thorax. 2016 Dec;71(12):1137-1144. doi: 10.1136/thoraxjnl-2015-208274. Epub 2016 Jul 26.
5
Inflammatory mechanisms in patients with chronic obstructive pulmonary disease.
J Allergy Clin Immunol. 2016 Jul;138(1):16-27. doi: 10.1016/j.jaci.2016.05.011. Epub 2016 May 27.
6
Pulmonary vasculature in COPD: The silent component.
Respirology. 2016 Aug;21(6):984-94. doi: 10.1111/resp.12772. Epub 2016 Mar 30.
8
Circulating desmosine levels do not predict emphysema progression but are associated with cardiovascular risk and mortality in COPD.
Eur Respir J. 2016 May;47(5):1365-73. doi: 10.1183/13993003.01824-2015. Epub 2016 Mar 23.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验